LLY

NEUTRALProduct

Eli Lilly and Company

2026-08-19

Price

$1280.34

+4.46%

This is the 2026-08-19 snapshot — the signals and analysis for LLY as of this single trading day.

View full LLY research hub →

Score9.5Priority

Signals4/8 DNA2/13 Act · 1/4 Risk

SentimentNEUTRALScore: 9

Volume1.7xvs 20d avg

Analysis

LLY is surging to all-time highs driven by a potent combination of real-time prescription share gains in the oral obesity market, fresh pipeline expansion deals, and massive Q2 earnings beats. This fundamental momentum is perfectly captured by PERFECT_STACK and BREAKOUT technical signals, with urgent institutional buying pushing volume to 1.7x its average. Furthermore, the RISK_ON macro regime, characterized by falling Treasury yields and tight credit spreads, provides an incredibly supportive backdrop for this high-conviction price discovery by expanding mega-cap growth multiples.

Fired Signals

ALPHA MALEGOLDEN CROSSMARKET LEADERPERFECT STACKQUIET ACCUMULATIONBREAKOUTWEAK FINISH

Key Takeaways

Actionable Thesis: Capitalize on the high-conviction breakout as LLY benefits from dominant GLP-1 market share and a highly supportive lower-yield macro environment.
Key Risk: Elevated valuation multiples leave the stock highly sensitive to any FDA regulatory scrutiny, pipeline setbacks, or pricing wars with competitors.
What to Watch: Monitor the $1115.68 line-in-the-sand support level and ongoing prescription volume data for Zepbound and the new oral GLP-1 Foundayo.

← Back to 2026-08-19 View Full LLY History →Yahoo Finance &nearr;